Ajanta Pharma Limited
AJANTPHARM.BO
Bombay Stock Exchange2,923.85
INR
-6.70
- -
Ajanta Pharma Limited
AJANTPHARM.BO
(Bombay Stock Exchange)
Recent
price
2,923.85
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ajanta Pharma Limited is a specialty pharmaceutical company headquartered in Mumbai, India, founded in 1973, with operations across India, Southeast Asia, the Middle East, Central Asia, Africa, the United States, and other international markets. The company primarily manufactures and markets branded generic medicines in therapeutic areas including ophthalmology, dermatology, cardiology, pain management, antimalarial, gastrointestinal, antibiotics, antihistamines, multivitamins, and gynecology, offering over 1,400 registered products with a strong pipeline of differentiated and niche therapies. Its product portfolio spans branded generics in emerging markets and generic pharmaceuticals in the US, with regulatory approvals including US FDA certifications at its manufacturing facilities. Ajanta Pharma maintains seven state-of-the-art manufacturing plants in India focused on finished formulations and active pharmaceutical ingredients primarily for captive consumption, supporting its extensive global distribution network. The company emphasizes innovation through first-to-market products targeting unmet patient needs using cutting-edge technology and a focused therapeutic segment strategy. Recent major developments include a strategic partnership with Credible Innovations, an AI-powered ESG bookkeeping and reporting service provider, aimed at enhancing Ajanta Pharma’s ESG data management and sustainability reporting aligned with global standards. In the fiscal years leading up to 2025, Ajanta Pharma reported steady revenue growth with revenue reaching over ₹4,200 crore and demonstrated healthy operating margins, supported by consistent new product launches including over 15 new formulations in regulated markets in 2023 and a significant ramp-up in ANDA filings and approvals in the US generics business. The company also executed a Rs. 285 crore share buyback program in 2024, reflecting strong financial health and shareholder return focus. Ajanta Pharma targets a diverse customer base including emerging market consumers through branded generics and patients in regulated markets like the US through its generics portfolio. The company has a diversified revenue stream, driving scalability and sustainability globally. It is led by a management team focused on innovation, sustainability, and strategic global expansion, aiming to consolidate leadership in multiple molecule segments while enhancing operational efficiencies and compliance with international regulatory standards. Ajanta Pharma’s continuous product development, geographic expansion, and strategic ESG initiatives position it as a key player in the global specialty pharmaceutical industry.